Fresenius Medical Care AG (Fresenius Medical Care AG) GF Value

: $24.87 (As of Today)

View and export this data going back to 1996. Start your Free Trial

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-23), Fresenius Medical Care AG's share price is $20.55. Fresenius Medical Care AG's GF Value is $24.87. Therefore, Fresenius Medical Care AG's Price-to-GF-Value for today is 0.83.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Fresenius Medical Care AG is Modestly Undervalued.

Fresenius Medical Care AG (NYSE:FMS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Fresenius Medical Care AG's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	20.55	/	24.87
	=	0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fresenius Medical Care AG GF Value Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

FMCQF:USA FME:Italy FMEd:UK 0H9X:UK FME:Germany FMEA:Germany FME:Germany FME:Germany FMEA:Germany FME:Germany FMSC34:Brazil FME:Austria

Address

Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352

Website

https://www.freseniusmedicalcare.com

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Executives

Helen Pring Giza

Board of Directors